Logo

GSK's Benlysta (belimumab) Receives EC's Approval for the Treatment of Active Lupus Nephritis

Share this
GSK's Benlysta (belimumab) Receives EC's Approval for the Treatment of Active Lupus Nephritis

GSK's Benlysta (belimumab) Receives EC's Approval for the Treatment of Active Lupus Nephritis

Shots:

  • The MAA is based on a P-III BLISS-LN study assessing the efficacy and safety of belimumab (10 mg/kg- IV) + standard therapy vs PBO + standard therapy in 448 patients with active lupus nephritis for 104 wks.
  • The study met its 1EPs i.e patients who achieved PERR @2yrs. (43% vs 32%) and has achieved all major 2EPs- 49% reduction in the risk of patients experiencing renal-related events- results were consistent with the known safety profile of Benlysta
  • Benlysta (IV- SC) is the first and only biologic approved for both SLE and LN in the EU. The EU’s MAA follows the recent approval for the similar expanded LN indication in the US

  Ref: GSK | Image: GSK

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions